Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2004
Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy
Ranjana Advani, Saul A Rosenberg, Sandra J Horning
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 13, 2018
Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy
Everett J Moding, Ranjana Advani, Saul A Rosenberg, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 1, 2021
Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies)
Eric Mou, Ranjana H Advani, Rie von Eyben, et al.
Oncology Research
|
March 16, 2010
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease
Holbrook Kohrt, Alexandre Johannsen, Richard Hoppe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2002
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
Sandra J Horning, Richard T Hoppe, Sheila Breslin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease
Ranjana Advani, Lauren Maeda, Philip Lavori, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience
Ranjana H Advani, Richard T Hoppe, Lauren S Maeda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2013
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials
Michael Zach Koontz, Sandra J Horning, Raymond Balise, et al.
Leukemia & Lymphoma
|
June 2, 2020
Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation
Christopher R Weil, Yushen Qian, Rie Von Eyben, et al.
American Journal of Clinical Oncology
|
January 7, 2014
Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma
Kathleen C Horst, Katherine E Fero, Steven L Hancock, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2004
Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy
Ranjana Advani, Saul A Rosenberg, Sandra J Horning
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 13, 2018
Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy
Everett J Moding, Ranjana Advani, Saul A Rosenberg, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 1, 2021
Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies)
Eric Mou, Ranjana H Advani, Rie von Eyben, et al.
Oncology Research
|
March 16, 2010
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease
Holbrook Kohrt, Alexandre Johannsen, Richard Hoppe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2002
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
Sandra J Horning, Richard T Hoppe, Sheila Breslin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease
Ranjana Advani, Lauren Maeda, Philip Lavori, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience
Ranjana H Advani, Richard T Hoppe, Lauren S Maeda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2013
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials
Michael Zach Koontz, Sandra J Horning, Raymond Balise, et al.
Leukemia & Lymphoma
|
June 2, 2020
Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation
Christopher R Weil, Yushen Qian, Rie Von Eyben, et al.
American Journal of Clinical Oncology
|
January 7, 2014
Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma
Kathleen C Horst, Katherine E Fero, Steven L Hancock, et al.
Page
of 2